49
Pharmacology of Antipsychotics Dr Andrew P Mallon

Pharmacology of Antipsychotics Dr Andrew P Mallon

Embed Size (px)

Citation preview

Page 1: Pharmacology of Antipsychotics Dr Andrew P Mallon

Pharmacology of Antipsychotics

Dr Andrew P Mallon

Page 2: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Page 3: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Dopamine Hypothesis

• Drugs that increase dopamine will enhance or produce positive psychotic symptoms– E.G. Cocaine, amphetamine

Page 4: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

• All known antipsychotics drugs capable of treating positive psychotic symptoms block the dopamine receptors– Esp..D-2 receptors

Dopamine Hypothesis

Page 5: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Dopamine Pathways

• Mesolimbic

• Nigrostriatal

• Mesocortical

• Tuberoinfundibular

Page 6: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Dopamine PathwaysMesolimbic

• Projects from brainstem to limbic areas.

• Overactivity produces delusions and hallucinations.

Page 7: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Dopamine PathwaysNigrostriatal

• Projects from the substania nigra to the basal ganglia

– A part of the extrapyramidal system

– Thus side effects are called “extrapyramidal”

Page 8: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Dopamine PathwaysNigrostriatal

• Controls movements

• The term “neuroleptics” refers to:

– Antipsychotics ability to “quiet the neurological system”

– To their neurological side effects

Page 9: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Dopamine PathwaysNigrostriatal

• Types of movement disorders caused by this pathway include:– Akathisia

– Dystonia

– Tremor, rigidity, bradykinesia • Drug-induced Parkinsonism

Page 10: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Dopamine PathwaysNigrostriatal

• Chronic blockade can cause

– Potentially irreversible movement disorder • “Tardive Dyskinesia”

• Role is undetermined

Page 11: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Dopamine PathwaysMesocortical

• May be associated with both positive and negative symptoms

• Blockade may help reduce negative symptoms of schizophrenia

• May be involved in the cognitive side effects of antipsychotics “mind dulling”

Page 12: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Dopamine PathwaysTuberoinfundibular

• Blockade produces galactorrhea

• Dopamine=PIF

Page 13: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Dopamine PathwaysSummary

• Four dopamine pathways– Appears that blocking dopamine

receptors in only one of them is useful

• Blocking dopamine receptors in the other three may be harmful

Page 14: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Page 15: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Antipsychotics

• Phenothiazines (piperidines)– Mesoridazine

• Serentil

– Thioridazine • Mellaril

• Phenothiazines (Aliphatic)– Chlorpromazine

• Thorazine

Page 16: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

AntipsychoticsPhenothiazines (piperazines)

• Perphenazine – Trilafon

• Trifluoperazine – Stelazine

• Fluphenazine – Prolixin

Page 17: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Antipsychotics

• Thioxanthenes– Navane

• Dibenzazepines– Clozapine

• Clozaril

– Ioxapine • Loxitane

Page 18: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Antipsychotics

• Butyrophenones– Haloperidol

• Haldol

• Diphenylbutylpiperidines– Pimozide

• Orap

Page 19: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Page 20: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Antipsychotics

• Indoles– Molindone

• Moban

• Rauwolfia– Reserpine

• Serpasil

Page 21: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Antipsychotics

• Benzisoxazole– Risperidone

• Risperdal

• Thienobenzodiazepines– Olanzapine

• Zyprexa

Page 22: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

AntipsychoticsEfficacy

• All antipsychotics are considered equally effective– Rationale for determining which

medication to use is based on side effect profile

• Primary mechanism of action is– Postsynaptic blockade of the D-2 receptor– “D-2, me too”

Page 23: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

AntipsychoticsEfficacy

• Newer agents– e.g. Clozaril

– Have significant activity at the D-1 receptor;

– Risperdal and Zyprexa have significant 5-HT2 activity

Page 24: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

AntipsychoticsPotency

• Potency is an important variable in terms of pharmacodynamic properties of these medicines.

• Potency determines the predictable side effects of the antipsychotics.

Page 25: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

AntipsychoticsPotency

• Low potency medications cause more:– sedation– Anti-ACH– Orthostatic hypotension

• High potency medications cause more:– EPS

Page 26: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Dopaminergic D2 Blockade

Possible Clinical Consequences• Extrapyramidal movement

disorders

• Endocrine changes

• Sexual dysfunction

Page 27: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

AntipsychoticsRelative potencies (mg

equivalents)

0

20

40

60

80

100 chlorpromazine(Thorazine)

thioridazine(Mellaril)mesoridazine(Serentil)

loxapine(Loxitane)

molindone(Moban)thiothixene(Navane)

trifluoperazine(Stelazine)

haloperidol(Haldol)fluphenazine(Prolixin)

Page 28: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Histamine H1 BlockadePossible Clinical Consequences

• Sedation, drowsiness

• Weight gain

• Hypotension

Page 29: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

AntipsychoticsPotency for H-1 blockade

0 5 10 15 20 25

chlorpromazine(Thorazine)

thioridazine(Mellaril)

loxapine(Loxitane)

molindone(Moban)

trifluoperazine(Stelazine)

fluphenazine(Prolixin)

haloperidol(Haldol)

haloperid 0.025

Page 30: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Alpha-1 receptor blockadePossible clinical consequences

• Postural hypotension

• Reflex tachycardia

• Dizziness

Page 31: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

0

5

10

15

20

25

30

35

40chlorpromazine(Thorazine)

thioridazine(Mellaril)

loxapine(Loxitane)

molindone(Moban)

trifluoperazine(Stelazine)

fluphenazine(Prolixin)

haloperidol(Haldol)

AntipsychoticsPotency for alpha-1 blockade

Page 32: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Muscarinic receptor blockade

Possible clinical consequences• Blurred vision

• Dry mouth

• Sinus tachycardia

• Constipation

• Urinary retention

• Memory dysfunction

Page 33: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

AntipsychoticsPotency for muscarinic

blockade

0

1

2

3

4

5

6

Series 1

chlorpromazine(Thorazine)

thioridazine(Mellaril)

loxapine(Loxitane)

molindone(Moban)

trifluoperazine(Stelazine)

fluphenazine(Prolixin)

haloperidol(Haldol)

Page 34: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Page 35: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

ClozarilClozapine

• “Atypical” antipsychotic

• More effective in person’s who fail typical antipsychotic therapy

• At least nine different receptor affinities

Page 36: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

ClozarilClozapine

• One of the most complicated medications in psychopharmacology

• Can cause death via agranulocytosis

• Cost is typically $10,000.00 per year

Page 37: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Extrapyramidal Symptoms

Dopamine Vs Acetylcholine• Dopamine and Acetylcholine have

a reciprocal relationship in the Nigrostriatal pathway.

• A delicate balance allows for normal movement.

Page 38: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Extrapyramidal Symptoms

Dopamine Vs Acetylcholine

• Dopamine blockade:

• A relative increase in cholinergic activity– causing EPS

– Those antipsychotics that have significant anti-ACH activity are therefore less likely to cause EPS

Page 39: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Extrapyramidal Symptoms

Dopamine Vs Acetylcholine• When high potency antipsychotics

are chosen, we often prescribe anti-ACH medication like

– Cogentin, diphenhydramine, or Artane

Page 40: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Tardive Dyskinesia

• Associated with long-term use of antipsychotics– (chronic dopamine blockade)

• Potentially irreversible involuntary movements around the buccal-lingual-oral area

Page 41: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Tardive Dyskinesia

• Attempt of decrease dose– will initially exacerbate the

movements

• Increasing the dose will initially decrease the movements

Page 42: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Neurological Side Effects:

• Dystonic Reactions:– Uncoordinated spastic movements of

muscle groups• Trunk, tongue, face

• Akinesia:– Decreased muscular movements

• Rigidity:– Coarse muscular movement– Loss of facial expression

Page 43: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Neurological Side Effects:

• Tremors:– Fine movement (shaking) of the extremities

• Akathisia:– Restlessness – Pacing

• May result in insomnia

• Tardive Dyskinesia:– Buccolinguo-masticalory syndrome– Choreoathetoid movements

Page 44: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Neurological Side Effects of Neuroleptics

3 6 9 12 15

A: DystonicReactions

B: Akinesia

C: Rigidity

D: Tremors

E: Akathisia

F: TardiveDykinesia

Page 45: Pharmacology of Antipsychotics Dr Andrew P Mallon

Neurological Effects

  Neurological Effects

Tardive Dyskinesia

Onset Acute or insidiousWithin 1 – 30 days

After months or years of treatment, especially if drug dose decreased or discontinued

Proposed Mechanism

Due to decreased dopamine

Supersensitivity of postsynaptic dopamine receptors induced by long term neuroleptic blockade

Treatment Respond to antiparkinsonian drugs

Generally worsen Tardive DyskinesiaOther treatments unsatisfactory; some aimed at balancing Dopaminergic and cholinergic systems. Can mask symptoms by further suppressing dopamine with neuroleptics. Pimozide or loxapine may least aggravate Tardive Dyskinesia.

Page 46: Pharmacology of Antipsychotics Dr Andrew P Mallon

Extrapyramidal Effects

Type Onset Risk Group

Clinical Course

Treatment

Dystonias Acute (within 5 days)

Young male Acute, painful, spasmodic Oculogyria may be recurrent

I.M. benztropine, I.M. diphenhydramine, sublingual lorazepam If symptoms recur, oral antiparkinsonian agents can be used

Akathisia Insidious to acute (within 10 days)

12-45% on neuroleptics

May continue though out treatment

I.M. benztropine, I.M. diphenhydramine, sublingual lorazepam If symptoms recur, oral antiparkinsonian agents can be used

Pseudoparkinsonism Insidious to acute (within 30 days)

12-45% on neuroleptics

May continue through treatment

Oral antiparkinsonian drug. Reduce or change neuroleptic

Page 47: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Neuroleptic Malignant Syndrome

• An idiosyncratic, life-threatening illness associated with antipsychotic

therapy

• Clinical manifestations include– hyperpyrexia – autonomic instability, – “board-like” rigidity

Page 48: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000

Neuroleptic Malignant Syndrome

• Resembles malignant hyperthermia associated with anesthesia

• Treatment involves – Immediate discontinuation of

antipsychotic – Hydration– Maintain vital functions – Prescribe bromocriptine and dantrolene

Page 49: Pharmacology of Antipsychotics Dr Andrew P Mallon

Douglas L. Geenens, D.O. 2000